PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis

• L Andreoli,
• E Morales,
• Z Amoura,
• P Korsten,
• A Jones-Leone,
• RA Levy,
• JA Gilbride,
• H Carnarius

Affiliations

L Andreoli

1Rheumatology and Clinical immunology, Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy

E Morales

Pediatrics Research Group, IMIB-Arrixaca Biomedical Research Institute, Murcia, Spain

Z Amoura

Internal Medicine Department, La Pitié-Salpétrière Hospital, 83 Boulevard de l’Hôpital, 75651 Paris Cedex 13, France

P Korsten

University Medical Centre Goettingen, Department of Nephrology and Rheumatology, Goettingen, Germany

A Jones-Leone

4GlaxoSmithKline, Global Medical Affairs ~ Collegeville ~ USA

RA Levy

4GlaxoSmithKline, Global Medical Affairs ~ Collegeville ~ USA

JA Gilbride

5GlaxoSmithKline, RandD Biostatistics ~ Stevenage ~ UK

H Carnarius

6GlaxoSmithKline, Specialty Care Medical Affairs ~ Hamburg ~ Germany